Kupando Raises €10 Million in Series A Funding
Kupando, a biopharmaceutical company based in Schönefeld, Brandenburg, Germany, has successfully raised €10 million in its Series A funding round. Known for its focus on developing therapies for cancer and infectious diseases, Kupando aims to leverage this funding to advance its innovative immunotherapy programs.
Investment Details
The Series A round was co-led by Remiges Ventures and LifeCare Partners. Other participants in this round included Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors, and Carma Fund. This substantial investment underscores the confidence investors have in Kupando's potential to make significant advancements in the field of immunotherapy.
Strategic Use of Funds
The funds raised will be primarily directed towards advancing the Phase 1b clinical study of Kupando's lead candidate, KUP101. This compound is a dual Toll-Like Receptor (TLR) agonist, specifically targeting TLR4 and TLR7, designed to activate the immune system to combat cancer and infections. The company plans to expand its research into treatment-resistant cancers and infectious diseases, with a particular focus on antimicrobial resistance and vaccine-related programs.
CEO and Founder Johanna Holldack emphasized the importance of addressing critical unmet medical needs, stating that the company is committed to "developing first-in-class immunotherapies" that could transform the treatment landscape for both cancer and infectious diseases.
Future Prospects
Beyond its lead candidate, Kupando is also working on a broader pipeline that includes therapies targeting various oncology indications, such as skin cancer and solid tumors, as well as infectious diseases. The company is harnessing the power of innate immune stimulation and trained immunity to develop these therapies, which have shown promising preclinical results.
Kupando's latest funding round marks a significant step forward in its mission to develop innovative treatments for some of the most challenging medical conditions. With the backing of prominent investors and a strong leadership team, Kupando is well-positioned to make meaningful contributions to the fields of oncology and infectious diseases.